Call Today: (800) 391-6415
Contact us for free information or to start a free case review.
Flolan is currently the only FDA approved drug for the treatment of primary pulmonary hypertension (PPH). Expected to raise the life expectancy of patients suffering from PPH, Flolan has extended the lives of patients using the drug by 3-5 years or more. PPH patients must continue the Flolan therapy for the rest of their lives with a regular increase in dosage. PPH causes a dangerously high blood pressure level in the pulmonary artery that connects the heart and lungs, leading to the heart being destroyed in some instances.
Primary pulmonary hypertension is a serious and non-curable disease that is predicted to increase according to medical researchers as a result of the high number of Fen Phen users. An estimated at 6-7 million people in the U.S. used Fen Phen and due to the 4-6 year latency period between Fen Phen use and PPH symptoms, diagnosis was often delayed. PPH sufferers will sometimes use Flolan or Tracleer therapy to prolong their life expectancy.
Copyright © 2001 - 2012 Online Lawyer Source | Legal Marketing Site Designed by eJustice
ATTORNEY ADVERTISEMENT—Thank you for your visit. The content published on this website was not written by medical professionals and should not, at any point, be mistaken for medical advice. Furthermore, the information on this site is intended for educational purposes only and should never interfere with a patient/site visitor and his or her healthcare provider. In addition, viewing the content on this website, requesting additional information, or transmitting information through a contact form should never be considered the formation of an attorney-client relationship. The material published on this site is general and may not apply to your specific circumstances. Every case comes with its own set of unique circumstances; past success discussed on this site does not guarantee future performance. Information found on this website should not be used as incentive to act without seeking counsel from a professional. For more information, please read our disclaimer.